Brief: AFT Pharmaceuticals Announces Exclusive Licensing Of Maxigesic IV
30/09/2024 02:00
Sept 30 (Reuters) - AFT Pharmaceuticals Ltd AFT.NZ :
* EXCLUSIVE LICENSING OF MAXIGESIC IV, INTRAVENOUS FORM OF
PROPRIETARY PAIN RELIEF MEDICINE, FOR CHINA
Further company coverage: AFT.NZ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AFT Pharmaceuticals
See all newsNZ's AFT Pharma eyes highest weekly gain in over 2 months after results
Brief: AFT Pharmaceuticals Reports Double Digit Revenue Growth In 1H FY27
NZ's AFT Pharmaceuticals gains most in over 2 weeks on strong half-year results
Brief: AFT Pharmaceuticals Enters Exclusive Development, License And Supply Agreement With Mikasaseiyaku
NZ's AFT Pharma rises to near 1-month high on Japan licensing deal for Maxigesic IV